세계의 특발성 혈소판 감소성 자반증 치료제 시장 : 시장 규모 분석(질환 종류별, 제품별, 투여 경로별, 연령층별, 유통 채널별, 지역별) 및 예측(2022-2032년)

The Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is valued at approximately USD 0.65 billion in 2023 and is anticipated to expand with a steady CAGR of more than 5.10% over the forecast period 2024-2032. Idiopathic Thrombocytopenic Purpura, a hematologic disorder marked by abnormally low levels of platelets due to immune system dysfunction, continues to demand advanced therapeutic interventions. The market is witnessing a notable transformation driven by heightened diagnostic awareness, a growing geriatric population susceptible to autoimmune conditions, and a more favorable reimbursement landscape. Treatments ranging from corticosteroids and immunoglobulins to thrombopoietin receptor agonists are undergoing clinical enhancements, while novel monoclonal antibodies and combination therapies are steadily advancing through pipelines. This paradigm shift reflects an urgent global demand for therapies that not only control bleeding risks but also improve patients' quality of life through sustainable platelet elevation.

The momentum in this market is significantly propelled by strategic alliances and innovations spearheaded by pharmaceutical powerhouses and biotech firms. These players are intensifying R&D efforts, particularly in the direction of targeted biologics and next-generation therapeutics with fewer side effects and better tolerability profiles. Regulatory bodies have shown increased responsiveness, granting orphan drug designations and breakthrough therapy statuses to expedite the commercialization of promising drug candidates. Additionally, patient-centric initiatives and educational campaigns have enhanced diagnosis rates, leading to a growing treatment-seeking population. However, market expansion remains somewhat restrained by the chronic nature of ITP, therapy relapse rates, high costs of biologics, and limited accessibility in lower-income regions, underscoring the need for affordability-centric innovation and public healthcare support.

As precision medicine continues to gain traction in immunohematology, the ITP therapeutics landscape is rapidly embracing personalized treatment regimens informed by genetic and immunological biomarkers. The integration of real-world data from electronic health records and AI-enabled analytics is facilitating more accurate therapeutic mapping and outcome prediction. This data-driven transformation is equipping healthcare providers to optimize drug usage and reduce unnecessary immunosuppressive exposure. Moreover, biopharma manufacturers are aggressively investing in biosimilar development to offset the financial burden associated with biologic therapies. The shifting treatment paradigm is favoring long-term maintenance therapies with minimal adverse effects, paving the way for sustained growth in this niche yet increasingly important therapeutic domain.

Regionally, North America leads the charge in market dominance due to robust healthcare infrastructure, high awareness levels, and a strong pipeline of approved drugs. The United States, in particular, has seen a surge in clinical trials and early access programs, contributing to the region's growth trajectory. Europe follows closely, with rising government investments in rare disease research and strong presence of multinational pharmaceutical entities. Meanwhile, the Asia Pacific region is poised for the fastest growth through 2032, driven by improvements in healthcare access, increasing diagnosis rates, and aggressive entry of generics. Countries like India and China are particularly focusing on strengthening their domestic manufacturing capabilities, which is expected to catalyze regional market expansion.

Major market player included in this report are:

• Novartis AG
• Amgen Inc.
• Grifols, S.A.
• CSL Behring
• Rigel Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Biogen Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Momenta Pharmaceuticals, Inc.
• Johnson & Johnson
• Akari Therapeutics
• Dova Pharmaceuticals
• UCB S.A.
• Shire (a Takeda company)

The detailed segments and sub-segment of the market are explained below:

By Disease Type

• Acute ITP
• Chronic ITP

By Product

• Corticosteroids
• Immunoglobulins
• Thrombopoietin Receptor Agonists
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Age Group

• Pediatrics
• Adults

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Executive Summary

• 1.1. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Disease Type
  • 1.3.2. By Product
  • 1.3.3. By Route of Administration
  • 1.3.4. By Age Group
  • 1.3.5. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Heightened Diagnostic Awareness and Early Detection
  • 3.1.2. Growing Geriatric Population and Autoimmune Prevalence
  • 3.1.3. Favorable Reimbursement Landscape and R&D Investments
• 3.2. Market Challenges
  • 3.2.1. High Cost of Biologics and Chronic Therapy Management
  • 3.2.2. Therapy Relapse Rates and Treatment Resistance
  • 3.2.3. Limited Accessibility in Emerging Economies
• 3.3. Market Opportunities
  • 3.3.1. Precision Medicine and Biomarker-Driven Therapies
  • 3.3.2. Integration of AI-Enabled Analytics in Treatment Mapping
  • 3.3.3. Biosimilar and Generic Entry to Reduce Treatment Costs

Chapter 4. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Size & Forecasts by Disease Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global ITP Therapeutics Market: Disease Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 5.2.1. Acute ITP
  • 5.2.2. Chronic ITP

Chapter 6. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Size & Forecasts by Product 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global ITP Therapeutics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 6.2.1. Corticosteroids
  • 6.2.2. Immunoglobulins
  • 6.2.3. Thrombopoietin Receptor Agonists
  • 6.2.4. Others

Chapter 7. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Size & Forecasts by Region 2022-2032

• 7.1. North America Market
  • 7.1.1. U.S. Market
    • 7.1.1.1. Disease Type Breakdown Size & Forecasts, 2022-2032
    • 7.1.1.2. Product Breakdown Size & Forecasts, 2022-2032
  • 7.1.2. Canada Market
• 7.2. Europe Market
  • 7.2.1. UK Market
  • 7.2.2. Germany Market
  • 7.2.3. France Market
  • 7.2.4. Spain Market
  • 7.2.5. Italy Market
  • 7.2.6. Rest of Europe Market
• 7.3. Asia Pacific Market
  • 7.3.1. China Market
  • 7.3.2. India Market
  • 7.3.3. Japan Market
  • 7.3.4. Australia Market
  • 7.3.5. South Korea Market
  • 7.3.6. Rest of Asia Pacific Market
• 7.4. Latin America Market
  • 7.4.1. Brazil Market
  • 7.4.2. Mexico Market
  • 7.4.3. Rest of Latin America Market
• 7.5. Middle East & Africa Market
  • 7.5.1. Saudi Arabia Market
  • 7.5.2. South Africa Market
  • 7.5.3. Rest of Middle East & Africa Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Novartis AG
  • 8.1.2. Amgen Inc.
  • 8.1.3. Grifols, S.A.
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Novartis AG
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Amgen Inc.
  • 8.3.3. Grifols, S.A.
  • 8.3.4. CSL Behring
  • 8.3.5. Rigel Pharmaceuticals, Inc.
  • 8.3.6. F. Hoffmann-La Roche Ltd.
  • 8.3.7. Biogen Inc.
  • 8.3.8. Pfizer Inc.
  • 8.3.9. Takeda Pharmaceutical Company Limited
  • 8.3.10. Momenta Pharmaceuticals, Inc.
  • 8.3.11. Johnson & Johnson
  • 8.3.12. Akari Therapeutics
  • 8.3.13. Dova Pharmaceuticals
  • 8.3.14. UCB S.A.
  • 8.3.15. Shire (a Takeda company)

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes